{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:19:24Z","timestamp":1783160364695,"version":"3.54.6"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12300-0","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:25:31Z","timestamp":1783153531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroprotective potential of resveratrol in Parkinson, Huntington, amyotrophic lateral sclerosis, and multiple sclerosis: a comprehensive review"],"prefix":"10.1007","volume":"53","author":[{"given":"Kasra","family":"Shahsavari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Yazarlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hananeh","family":"Ahmadnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa Tavakolian","family":"Ardakani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Khanavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza Monsef","family":"Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Abdollahzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Sajedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Kazemizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8260-6123","authenticated-orcid":false,"given":"Maede","family":"Hasanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"12300_CR1","doi-asserted-by":"crossref","unstructured":"Dugger BN, Dickson DW (2017) Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol (7):a028035","DOI":"10.1101\/cshperspect.a028035"},{"key":"12300_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-017-0077-5","volume":"6","author":"P Sweeney","year":"2017","unstructured":"Sweeney P et al (2017) Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener 6:6","journal-title":"Transl Neurodegener"},{"issue":"2","key":"12300_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/imm.12922","volume":"154","author":"J Stephenson","year":"2018","unstructured":"Stephenson J et al (2018) Inflammation in CNS neurodegenerative diseases. Immunology 154(2):204\u2013219","journal-title":"Immunology"},{"issue":"1","key":"12300_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W et al (2017) Parkinson disease. Nat Rev Dis Primers 3(1):1\u201321","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"12300_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4161\/oxim.2.5.9498","volume":"2","author":"KB Pandey","year":"2009","unstructured":"Pandey KB, Rizvi SI (2009) Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev 2(5):270\u2013278","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"12300_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd2060","volume":"5","author":"JA Baur","year":"2006","unstructured":"Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5(6):493\u2013506","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"12300_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.bbadis.2010.01.011","volume":"1802","author":"LF Barbosa","year":"2010","unstructured":"Barbosa LF et al (2010) Increased SOD1 association with chromatin, DNA damage, p53 activation, and apoptosis in a cellular model of SOD1-linked ALS. Biochim Biophys Acta 1802(5):462\u201371","journal-title":"Biochim Biophys Acta"},{"key":"12300_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fnagi.2020.00103","volume":"12","author":"BD Arbo","year":"2020","unstructured":"Arbo BD et al (2020) Resveratrol Derivatives as Potential Treatments for Alzheimer\u2019s and Parkinson\u2019s Disease. Front Aging Neurosci 12:103","journal-title":"Front Aging Neurosci"},{"key":"12300_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9080918","author":"HC Kung","year":"2021","unstructured":"Kung HC et al (2021) Oxidative stress, mitochondrial dysfunction, and neuroprotection of polyphenols with respect to resveratrol in Parkinson\u2019s disease. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines9080918","journal-title":"Biomedicines"},{"issue":"9680","key":"12300_CR10","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","volume":"373","author":"AJ Lees","year":"2009","unstructured":"Lees AJ, Hardy J, Revesz T (2009) Parkinson\u2019s disease. Lancet 373(9680):2055\u201366","journal-title":"Lancet"},{"issue":"1\u20133","key":"12300_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejphar.2008.10.005","volume":"600","author":"F Jin","year":"2008","unstructured":"Jin F et al (2008) Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson\u2019s disease in rats. Eur J Pharmacol 600(1\u20133):78\u201382","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"12300_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000328516","volume":"19","author":"Y Wu","year":"2011","unstructured":"Wu Y et al (2011) Resveratrol-activated AMPK\/SIRT1\/autophagy in cellular models of Parkinson\u2019s disease. Neurosignals 19(3):163\u2013174","journal-title":"Neurosignals"},{"issue":"5","key":"12300_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/biof.118","volume":"36","author":"D Albani","year":"2010","unstructured":"Albani D et al (2010) Neuroprotective properties of resveratrol in different neurodegenerative disorders. BioFactors 36(5):370\u2013376","journal-title":"BioFactors"},{"key":"12300_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.brainres.2010.02.031","volume":"1328","author":"MM Khan","year":"2010","unstructured":"Khan MM et al (2010) Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson\u2019s disease. Brain Res 1328:139\u2013151","journal-title":"Brain Res"},{"issue":"1","key":"12300_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ (2011) Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10(1):83\u201398","journal-title":"Lancet Neurol"},{"issue":"4","key":"12300_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/ng1534","volume":"37","author":"JA Parker","year":"2005","unstructured":"Parker JA et al (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37(4):349\u2013350","journal-title":"Nat Genet"},{"issue":"1","key":"12300_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.expneurol.2010.05.006","volume":"225","author":"DJ Ho","year":"2010","unstructured":"Ho DJ et al (2010) Resveratrol protects against peripheral deficits in a mouse model of Huntington\u2019s disease. Exp Neurol 225(1):74\u201384","journal-title":"Exp Neurol"},{"issue":"2","key":"12300_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/hmg\/ddq460","volume":"20","author":"P Maher","year":"2011","unstructured":"Maher P et al (2011) ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington\u2019s disease. Hum Mol Genet 20(2):261\u2013270","journal-title":"Hum Mol Genet"},{"issue":"11","key":"12300_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","volume":"7","author":"O Hardiman","year":"2011","unstructured":"Hardiman O, van den Berg LH, Kiernan MC (2011) Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 7(11):639\u201349","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"12300_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13311-013-0253-y","volume":"11","author":"R Mancuso","year":"2014","unstructured":"Mancuso R et al (2014) Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. Neurotherapeutics 11(2):419\u201332","journal-title":"Neurotherapeutics"},{"issue":"5","key":"12300_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1089\/jmf.2009.0243","volume":"13","author":"CD Markert","year":"2010","unstructured":"Markert CD et al (2010) A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis. J Med Food 13(5):1081\u20131085","journal-title":"J Med Food"},{"issue":"3","key":"12300_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.neulet.2011.08.047","volume":"503","author":"J Wang","year":"2011","unstructured":"Wang J et al (2011) Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis. Neurosci Lett 503(3):250\u2013255","journal-title":"Neurosci Lett"},{"issue":"1","key":"12300_CR23","first-page":"110","volume":"13","author":"YC Yun","year":"2019","unstructured":"Yun YC et al (2019) Reduced sirtuin 1\/adenosine monophosphate-activated protein kinase in amyotrophic lateral sclerosis patient-derived mesenchymal stem cells can be restored by resveratrol. J Tissue Eng Regen Med 13(1):110\u2013115","journal-title":"J Tissue Eng Regen Med"},{"issue":"10130","key":"12300_CR24","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ et al (2018) Multiple sclerosis. Lancet 391(10130):1622\u20131636","journal-title":"Lancet"},{"issue":"6","key":"12300_CR25","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1124\/mol.107.038984","volume":"72","author":"NP Singh","year":"2007","unstructured":"Singh NP et al (2007) Resveratrol (trans-3,5,4\u2019-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 72(6):1508\u201321","journal-title":"Mol Pharmacol"},{"issue":"9","key":"12300_CR26","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.4049\/jimmunol.1202584","volume":"190","author":"VK Nimmagadda","year":"2013","unstructured":"Nimmagadda VK et al (2013) Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets. J Immunol 190(9):4595\u20134607","journal-title":"J Immunol"},{"key":"12300_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3389\/fneur.2012.00084","volume":"3","author":"Z Fonseca-Kelly","year":"2012","unstructured":"Fonseca-Kelly Z et al (2012) Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol 3:84","journal-title":"Front Neurol"},{"issue":"10291","key":"12300_CR28","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397(10291):2284\u20132303","journal-title":"Lancet"},{"issue":"9996","key":"12300_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386(9996):896\u2013912","journal-title":"Lancet"},{"key":"12300_CR30","doi-asserted-by":"crossref","unstructured":"Shen DF et al (2023) Resveratrol Promotes Autophagy to Improve neuronal Injury in Parkinson\u2019s Disease by Regulating SNHG1\/miR-128-3p\/SNCA Axis. Brain Sci, 13(8)","DOI":"10.3390\/brainsci13081124"},{"key":"12300_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.biopha.2015.08.025","volume":"74","author":"ZH Wang","year":"2015","unstructured":"Wang ZH et al (2015) MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting alpha-synuclein expression in MPTP-induced Parkinson\u2019s disease mouse. Biomed Pharmacother 74:252\u2013256","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"12300_CR32","doi-asserted-by":"publisher","first-page":"6636","DOI":"10.1007\/s12035-024-04234-0","volume":"62","author":"S Feng","year":"2025","unstructured":"Feng S et al (2025) Resveratrol Inhibits VDAC1-Mediated Mitochondrial Dysfunction to Mitigate Pathological Progression in Parkinson\u2019s Disease Model. Mol Neurobiol 62(6):6636\u20136654","journal-title":"Mol Neurobiol"},{"issue":"4","key":"12300_CR33","doi-asserted-by":"publisher","first-page":"4942","DOI":"10.1002\/jcb.27769","volume":"120","author":"D Xia","year":"2019","unstructured":"Xia D, Sui R, Zhang Z (2019) Administration of resveratrol improved Parkinson\u2019s disease-like phenotype by suppressing apoptosis of neurons via modulating the MALAT1\/miR-129\/SNCA signaling pathway. J Cell Biochem 120(4):4942\u20134951","journal-title":"J Cell Biochem"},{"issue":"7","key":"12300_CR34","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.bbadis.2014.02.010","volume":"1842","author":"A Ferretta","year":"2014","unstructured":"Ferretta A et al (2014) Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson\u2019s disease. Biochim Biophys Acta 1842(7):902\u2013915","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"12300_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00210-018-1474-8","volume":"391","author":"S Palle","year":"2018","unstructured":"Palle S, Neerati P (2018) Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol 391(4):445\u2013453","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"12300_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cbi.2016.03.023","volume":"251","author":"HH Gaballah","year":"2016","unstructured":"Gaballah HH et al (2016) Modulatory effects of resveratrol on endoplasmic reticulum stress-associated apoptosis and oxido-inflammatory markers in a rat model of rotenone-induced Parkinson\u2019s disease. Chem Biol Interact 251:10\u201316","journal-title":"Chem Biol Interact"},{"issue":"3","key":"12300_CR37","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1753425913488429","volume":"20","author":"DD Lofrumento","year":"2014","unstructured":"Lofrumento DD et al (2014) Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson\u2019s-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun 20(3):249\u2013260","journal-title":"Innate Immun"},{"key":"12300_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bbr.2019.03.043","volume":"367","author":"Q Liu","year":"2019","unstructured":"Liu Q et al (2019) Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice. Behav Brain Res 367:10\u201318","journal-title":"Behav Brain Res"},{"key":"12300_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103707","volume":"97","author":"W Li","year":"2020","unstructured":"Li W et al (2020) Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson\u2019s disease. Bioorg Chem 97:103707","journal-title":"Bioorg Chem"},{"key":"12300_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.nbd.2012.10.011","volume":"51","author":"DN Hauser","year":"2013","unstructured":"Hauser DN, Hastings TG (2013) Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease and monogenic parkinsonism. Neurobiol Dis 51:35\u201342","journal-title":"Neurobiol Dis"},{"issue":"1","key":"12300_CR41","first-page":"S287","volume":"147","author":"MB Youdim","year":"2006","unstructured":"Youdim MB, Bakhle YS (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson\u2019s disease and depressive illness. Br J Pharmacol 147(1):S287\u2013S296","journal-title":"Br J Pharmacol"},{"issue":"3","key":"12300_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","volume":"38","author":"L Di","year":"2003","unstructured":"Di L et al (2003) High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 38(3):223\u2013232","journal-title":"Eur J Med Chem"},{"key":"12300_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2024.214065","volume":"166","author":"JT Yang","year":"2025","unstructured":"Yang JT et al (2025) Resveratrol and ceftriaxone encapsulated in hybrid nanoparticles to prevent dopaminergic neurons from degeneration for Parkinson\u2019s disease treatment. Biomater Adv 166:214065","journal-title":"Biomater Adv"},{"issue":"12","key":"12300_CR44","doi-asserted-by":"publisher","first-page":"17124","DOI":"10.1021\/acssuschemeng.8b04507","volume":"6","author":"M Wang","year":"2018","unstructured":"Wang M et al (2018) Magnetic Resveratrol Liposomes as a New Theranostic Platform for Magnetic Resonance Imaging Guided Parkinson\u2019s Disease Targeting Therapy. ACS Sustain Chem Eng 6(12):17124\u201317133","journal-title":"ACS Sustain Chem Eng"},{"key":"12300_CR45","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.actbio.2020.11.015","volume":"119","author":"YC Kuo","year":"2021","unstructured":"Kuo YC, Wang IH, Rajesh R (2021) Use of leptin-conjugated phosphatidic acid liposomes with resveratrol and epigallocatechin gallate to protect dopaminergic neurons against apoptosis for Parkinson\u2019s disease therapy. Acta Biomater 119:360\u2013374","journal-title":"Acta Biomater"},{"issue":"3","key":"12300_CR46","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s13346-024-01656-0","volume":"15","author":"A Bandiwadekar","year":"2025","unstructured":"Bandiwadekar A et al (2025) Transdermal delivery of resveratrol loaded solid lipid nanoparticle as a microneedle patch: a novel approach for the treatment of Parkinson\u2019s disease. Drug Deliv Transl Res 15(3):1043\u20131073","journal-title":"Drug Deliv Transl Res"},{"key":"12300_CR47","first-page":"3","volume-title":"Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis","author":"A Kouli","year":"2018","unstructured":"Kouli A, Torsney KM, Kuan W-L (2018) Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis. Exon Publications, pp 3\u201326"},{"issue":"1","key":"12300_CR48","first-page":"1","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman O et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3(1):1\u201319","journal-title":"Nat Rev Dis Primers"},{"issue":"5796","key":"12300_CR49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130\u2013133","journal-title":"Science"},{"issue":"11","key":"12300_CR50","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrneurol.2011.152","volume":"7","author":"L Ferraiuolo","year":"2011","unstructured":"Ferraiuolo L et al (2011) Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol 7(11):616\u2013630","journal-title":"Nat Rev Neurol"},{"key":"12300_CR51","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neurobiolaging.2021.07.008","volume":"108","author":"S Edgar","year":"2021","unstructured":"Edgar S et al (2021) Mutation analysis of SOD1, C9orf72, TARDBP and FUS genes in ethnically-diverse Malaysian patients with amyotrophic lateral sclerosis (ALS). Neurobiol Aging 108:200\u2013206","journal-title":"Neurobiol Aging"},{"issue":"16","key":"12300_CR52","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/hmg\/ddz104","volume":"28","author":"CO Wong","year":"2019","unstructured":"Wong CO, Venkatachalam K (2019) Motor neurons from ALS patients with mutations in C9ORF72 and SOD1 exhibit distinct transcriptional landscapes. Hum Mol Genet 28(16):2799\u20132810","journal-title":"Hum Mol Genet"},{"issue":"9769","key":"12300_CR53","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","volume":"377","author":"MC Kiernan","year":"2011","unstructured":"Kiernan MC et al (2011) Amyotrophic lateral sclerosis. Lancet 377(9769):942\u2013955","journal-title":"Lancet"},{"issue":"4","key":"12300_CR54","doi-asserted-by":"publisher","first-page":"E751","DOI":"10.1152\/ajpendo.00745.2009","volume":"298","author":"NB Ruderman","year":"2010","unstructured":"Ruderman NB et al (2010) AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab 298(4):E751\u2013E760","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"13","key":"12300_CR55","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1038\/sj.emboj.7601758","volume":"26","author":"D Kim","year":"2007","unstructured":"Kim D et al (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer\u2019s disease and amyotrophic lateral sclerosis. EMBO J 26(13):3169\u20133179","journal-title":"EMBO J"},{"key":"12300_CR56","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.brainres.2011.09.025","volume":"1423","author":"M Yanez","year":"2011","unstructured":"Yanez M et al (2011) CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: protection by resveratrol but not riluzole. Brain Res 1423:77\u201386","journal-title":"Brain Res"},{"issue":"9","key":"12300_CR57","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.tins.2005.07.001","volume":"28","author":"F von Lewinski","year":"2005","unstructured":"von Lewinski F, Keller BU (2005) Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci 28(9):494\u2013500","journal-title":"Trends Neurosci"},{"issue":"2","key":"12300_CR58","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/mus.20255","volume":"31","author":"MJ Hamadeh","year":"2005","unstructured":"Hamadeh MJ et al (2005) Caloric restriction transiently improves motor performance but hastens clinical onset of disease in the Cu\/Zn-superoxide dismutase mutant G93A mouse. Muscle Nerve 31(2):214\u2013220","journal-title":"Muscle Nerve"},{"issue":"8","key":"12300_CR59","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1167\/iovs.07-0131","volume":"48","author":"KS Shindler","year":"2007","unstructured":"Shindler KS et al (2007) SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 48(8):3602\u20133609","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"12300_CR60","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/WNO.0b013e3181f7f833","volume":"30","author":"KS Shindler","year":"2010","unstructured":"Shindler KS et al (2010) Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol 30(4):328\u2013339","journal-title":"J Neuroophthalmol"},{"issue":"5","key":"12300_CR61","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1007\/s12035-016-9891-5","volume":"54","author":"HR Ghaiad","year":"2017","unstructured":"Ghaiad HR et al (2017) Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study. Mol Neurobiol 54(5):3219\u20133229","journal-title":"Mol Neurobiol"},{"issue":"3","key":"12300_CR62","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s11481-019-09842-5","volume":"14","author":"KAO Gandy","year":"2019","unstructured":"Gandy KAO et al (2019) Resveratrol (3, 5, 4\u2019-Trihydroxy-trans-Stilbene) Attenuates a Mouse Model of Multiple Sclerosis by Altering the miR-124\/Sphingosine Kinase 1 Axis in Encephalitogenic T Cells in the Brain. J Neuroimmune Pharmacol 14(3):462\u2013477","journal-title":"J Neuroimmune Pharmacol"},{"key":"12300_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25074047","author":"E Shamsher","year":"2024","unstructured":"Shamsher E et al (2024) Intranasal resveratrol nanoparticles enhance neuroprotection in a model of multiple sclerosis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25074047","journal-title":"Int J Mol Sci"},{"key":"12300_CR64","doi-asserted-by":"crossref","unstructured":"Dhuria SV, Hanson LR, Frey WH 2 (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99(4):1654\u20131673","DOI":"10.1002\/jps.21924"},{"issue":"6","key":"12300_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/biom12060830","volume":"12","author":"AG Ross","year":"2022","unstructured":"Ross AG et al (2022) Selective upregulation of SIRT1 expression in retinal ganglion cells by AAV-mediated gene delivery increases neuronal cell survival and alleviates axon demyelination associated with optic neuritis. Biomolecules 12(6):830","journal-title":"Biomolecules"},{"issue":"8","key":"12300_CR66","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD (2021) Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA 325(8):765\u2013779","journal-title":"JAMA"},{"key":"12300_CR67","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jconrel.2022.12.026","volume":"353","author":"X Zheng","year":"2023","unstructured":"Zheng X et al (2023) Resveratrol-loaded macrophage exosomes alleviate multiple sclerosis through targeting microglia. J Control Release 353:675\u2013684","journal-title":"J Control Release"},{"issue":"7","key":"12300_CR68","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1080\/1028415X.2024.2425649","volume":"28","author":"S Keramatzadeh","year":"2025","unstructured":"Keramatzadeh S et al (2025) Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial. Nutr Neurosci 28(7):854\u2013862","journal-title":"Nutr Neurosci"},{"issue":"5\u20136","key":"12300_CR69","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","volume":"81","author":"C Zuccato","year":"2007","unstructured":"Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington\u2019s disease. Prog Neurobiol 81(5\u20136):294\u2013330","journal-title":"Prog Neurobiol"},{"issue":"9557","key":"12300_CR70","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO (2007) Huntington\u2019s disease. Lancet (London, England) 369(9557):218\u2013228","journal-title":"Lancet (London, England)"},{"issue":"1","key":"12300_CR71","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nm.2558","volume":"18","author":"M Jiang","year":"2012","unstructured":"Jiang M et al (2012) Neuroprotective role of Sirt1 in mammalian models of Huntington\u2019s disease through activation of multiple Sirt1 targets. Nat Med 18(1):153\u2013158","journal-title":"Nat Med"},{"issue":"1","key":"12300_CR72","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nm.2559","volume":"18","author":"H Jeong","year":"2012","unstructured":"Jeong H et al (2012) Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18(1):159\u2013165","journal-title":"Nat Med"},{"issue":"7","key":"12300_CR73","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1007\/s12035-016-0048-3","volume":"54","author":"L Naia","year":"2017","unstructured":"Naia L et al (2017) Comparative mitochondrial-based protective effects of resveratrol and nicotinamide in Huntington\u2019s disease models. Mol Neurobiol 54(7):5385\u20135399","journal-title":"Mol Neurobiol"},{"issue":"1","key":"12300_CR74","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00210-024-03319-w","volume":"398","author":"L Zhu","year":"2025","unstructured":"Zhu L et al (2025) Interaction between resveratrol and SIRT1: role in neurodegenerative diseases. Naunyn Schmiedebergs Arch Pharmacol 398(1):89\u2013101","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6954","key":"12300_CR75","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nature01960","volume":"425","author":"KT Howitz","year":"2003","unstructured":"Howitz KT et al (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425(6954):191\u2013196","journal-title":"Nature"},{"issue":"6","key":"12300_CR76","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1747-0285.2009.00901.x","volume":"74","author":"D Beher","year":"2009","unstructured":"Beher D et al (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74(6):619\u2013624","journal-title":"Chem Biol Drug Des"},{"issue":"11","key":"12300_CR77","doi-asserted-by":"publisher","first-page":"8340","DOI":"10.1074\/jbc.M109.088682","volume":"285","author":"M Pacholec","year":"2010","unstructured":"Pacholec M et al (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285(11):8340\u20138351","journal-title":"J Biol Chem"},{"issue":"3","key":"12300_CR78","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cell.2012.01.017","volume":"148","author":"SJ Park","year":"2012","unstructured":"Park SJ et al (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148(3):421\u2013433","journal-title":"Cell"},{"issue":"6","key":"12300_CR79","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","volume":"127","author":"M Lagouge","year":"2006","unstructured":"Lagouge M et al (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127(6):1109\u20131122","journal-title":"Cell"},{"issue":"6","key":"12300_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202200629","volume":"18","author":"Z Cao","year":"2023","unstructured":"Cao Z et al (2023) 2-Hydroxy-4-benzyloxylimine resveratrol derivatives as potential multifunctional agents for the treatment of Parkinson\u2019s disease. ChemMedChem 18(6):e202200629","journal-title":"ChemMedChem"},{"issue":"10","key":"12300_CR81","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1039\/D2FO03379H","volume":"14","author":"J Tao","year":"2023","unstructured":"Tao J et al (2023) The protective role of microbiota in the prevention of MPTP\/P-induced Parkinson\u2019s disease by resveratrol. Food Funct 14(10):4647\u20134661","journal-title":"Food Funct"},{"issue":"48","key":"12300_CR82","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/25\/48\/485102","volume":"25","author":"R Pangeni","year":"2014","unstructured":"Pangeni R et al (2014) Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson\u2019s disease by reducing oxidative stress. Nanotechnology 25(48):485102","journal-title":"Nanotechnology"},{"issue":"1","key":"12300_CR83","doi-asserted-by":"publisher","first-page":"17769","DOI":"10.1038\/s41598-025-00698-9","volume":"15","author":"AO Abolaji","year":"2025","unstructured":"Abolaji AO et al (2025) Experimental and computational insights into the therapeutic mechanisms of resveratrol in a Drosophila alpha-synuclein model of Parkinson\u2019s disease. Sci Rep 15(1):17769","journal-title":"Sci Rep"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12300-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12300-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12300-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:01:50Z","timestamp":1783159310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12300-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12300"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12300-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a review article. Therefore, ethical approval is not required for the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement and Consent to Participate"}},{"value":"No animals\/humans were used for studies that are the basis of this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}],"article-number":"1102"}}